Metabolic Syndrome Resolved within Two Years is Still a Risk Factor for Kidney Cancer

Area of Science:

• Oncology
• Metabolic Diseases
• Epidemiology

Background:

• The prevalence of metabolic syndrome (MetS) and kidney cancer is rising globally.
• Previous studies on the association between MetS and kidney cancer risk have yielded inconsistent results.

Purpose of the Study:

• To investigate the independent association between metabolic syndrome (MetS) and the risk of developing kidney cancer.
• To determine the impact of individual MetS components on kidney cancer risk.

Main Methods:

• Analysis of a large cohort of 7,613,865 patients from the Korean National Health Insurance System, followed up until 2017.
• Diagnosis of MetS based on the presence of at least three of the five defined components.
• Utilized the Cox proportional hazard regression model to assess the independent association between MetS and kidney cancer development.

Main Results:

• Patients diagnosed with MetS exhibited a significantly higher risk of developing kidney cancer, irrespective of sex.
• Kidney cancer risk escalated with an increasing number of MetS components.
• Individuals with abdominal obesity and hypertension, even without a formal MetS diagnosis, showed a similar kidney cancer risk to those with MetS.
• Patients who improved their MetS status within two years still had an increased kidney cancer risk compared to those without MetS.

Conclusions:

• Metabolic syndrome (MetS) is identified as an independent risk factor for kidney cancer.
• Obesity and hypertension, key components of MetS, are also identified as potent risk factors for kidney cancer development.